zurück Home

GELA

allgemeines

 Groupe d'Etude des Lymphomes de l'Adulte französische Lymphom - Studiengruppe
LNH87-1 mBACOD x 8 v ACVBP x 3 + sequenzielle Konsolidierungstherapie (1)
LNH87-2 ACVBP x 4 (4/3) v NCVBP x 4 (1/4); bei Response: sequenzielle Konsolidierungstherapie v HDT-ASCT (2)
LNH87-3 ACVBP x 4 + sequenzielle Konsolidierungstherapie (0/0) v alternierendes Regime (7/0) (3)
LNH87-4 CTVP x 6 (0/0) v CVP x 6 (3/0) (4)
LNH93-1 ACVBP x 3 + sequenzielle Konsolidierungstherapie (4/6) v CHOP x 3 + IFRT (1/4) (5)
LNH93-2 ACVBP x 4 + sequenzielle Konsolidierungstherapie (4/5) v ECVBP + IVAM (2/4) (6)
LNH93-3 ACVBP x 4 + sequenzielle Konsolidierungstherapie (5/7) v CEOP x 1 + ECVBP x 2 + HDT-ASCT (1/0) (7)
LNH93-4 CHOP x 4 (1/1) v CHOP x 4 + IFRT (3/2) (8)
LNH93-5 ACVBP x 4 + sequenzielle Konsolidierungstherapie (4/1) v CHOP x 8 (3/1) (9)
LNH93-6 CEOP x 6 (2/1) v miniCEOP x 6 (0/0)
LNH93-7 miniCEOP x 6 (0/0) v VCP x 6 (1/0)
LNH98-2 ACVBP x 4 + sequenzielle Konsolidierungstherapie (10/11) (10)
LNH98-3 ACVBP x 4 + HDT-ASCT (7/7) (11)
LNH98-5 CHOP x 8 (1/0)
LNH98-6 ACVBP x 4 + sequenzielle Konsolidierungstherapie (4/0)
Quellen 1. Tilly H, et al:
Randomized comparison of ACVBP andm-BACOD in the treatment of patients with low-risk aggressive lymphoma: The LNH87-1 study—Groupe d’E´ tudes des Lymphomes de l’Adulte.
J Clin Oncol 18(2000):1309-1315

2. Haioun C, et al:
Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin’s lymphoma: Final analysis of the prospective LNH87-2 protocol—A Groupe d’E´ tude des Lymphomes de l’Adulte study.
J Clin Oncol 18(2000):3025-3030

3. Bosly A, et al:
Outcome is not improved by the use of alternating chemotherapy in elderly patients with aggressive lymphoma.
Hematol J 2(2001):279-285

4. Bastion Y, et al:
Elderly patients with aggressive non-Hodgkin’s lymphoma: Disease presentation, response to treatment, and survival—A Groupe d’E´ tude des Lymphomes de l’Adulte study on 453 patients older than 69 years.
J Clin Oncol 15(1997):2945-2953

5. Reyes F, et al:
ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma.
N Engl J Med 352(2005):1197-1205

6. Morel P, et al:
Comparison of two high-dose cyclophosphamide, doxorubicin, vincristine, and prednisone derived regimens in patients aged under 60 years with low-intermediate risk aggressive lymphoma: A final analysis of the multicenter LNH93-2 protocol.
Leuk Lymphoma 51(2010):1668-1677

7. Gisselbrecht C, et al:
Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma.
J Clin Oncol 20(2002):2472-2479

8. Bonnet C, et al:
CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: A study by the Groupe d’E´ tude des Lymphomes de l’Adulte.
J Clin Oncol 25(2007):787-792

9. Tilly H, et al:
Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma.
Blood 102(2003):4284-4289

10. Morel P, et al:
Autologous stem-cell transplantation as consolidation therapy for diffuse large B-cell lymphoma patients with overexpression of BCL-2 protein: Results of the Groupe d’E´ tude des Lymphomes de l’Adulte (GELA) trial LNH98–B2.
Ann Oncol 19(2008):560-565

11. Haioun C, et al:
Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma.
Ann Oncol 202009:1985-1992

blauer Punkt

Impressum                             Zuletzt geändert am 28.08.2015 7:45